New developments around histamine H₃ receptor antagonists/inverse agonists: a patent review (2010 – present)

Abstract

Introduction: Histamine H₃ receptor (H₃R) is involved in the central and peripheral regulation of levels of histamine and other neurotransmitters (e.g., acetylcholine, noradrenaline, dopamine or serotonin). H₃R antagonists/inverse agonists constitute attractive targets in the search for new drugs. Preclinical data indicate their potential utility in the treatment of various central nervous system (CNS), metabolic, pain and allergic disorders. So far, many structurally diverse H₃R ligands have been synthesized and pharmacologically evaluated. Certain compounds have reached clinical trials. The first results from these studies have appeared.

Areas covered: The literature covering patent applications (2010 through June 2013) found in the Espacenet database will be reported.

Expert opinion: In comparison with previous years, recently the number of patent applications concerning H₃R antagonists/inverse agonists has decreased. The utility of compounds is still being verified in pharmacological studies. The first published results from clinical trials have shown not only positive effects but also emerging drawbacks. So far, BF2.649 is the most advanced in human trials (tiprolisant; Phase III trials). New ligands are being intensively tested in preclinical tests. Thus, it is expected that they will soon undergo clinical trials.

Keywords::

• clinical trials
• drug discovery
• H3 antagonist/inverse agonist
• histamine H3 receptor
• patent applications

Notes

This box summarizes key points contained in the article.